> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period for Teva’s Ajovy
- URL: https://www.fdaweb.com/regulatory-review-period-for-tevas-ajovy/
- Published: 2021-07-09T12:00:00.000Z
- Updated: 2026-09-14T17:05:45.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5149673

*Federal Register* notice: FDA has determined for patent extension purposes the regulatory review period for Teva Pharmaceuticals’ Ajovy (fremanezumab-vfrm), indicated for preventing migraines in adults. The regulatory review period is 3,216 days, which includes 2,882 days that occurred during the testing phase and 334 days during the approval phase. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-07-09/pdf/2021-14652.pdf?ref=fdaweb.com).